$GLUE

Monte Rosa Therapeutics reported a Q2 2026 net loss of $43.4M, with collaboration revenue of $9.0M. Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0M as of June 30, 2026, supporting operations into 2029. R&D and G&A rose year over year. The company advanced MRT-8102 and other programs, including Novartis-activated MRT-6160 Phase 2.

Monte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout

BioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) fell after Novo Nordisk (NVO) reported its late-stage ZEUS trial for ziltivekimab failed to reduce heart attack, stroke, and related deaths despite lowering inflammation markers. BIOA dropped 64% and GLUE about 27%. Analysts cut BIOA and GLUE price targets while keeping Buy ratings.

Amazon shares rally as cloud growth surges and spending outlook climbs Investing.com -- Monte Rosa Therapeutics shares plummeted nearly 29.9% in pre-open trading today, trading at $15.90, after Novo Nordisk disclosed that its Phase 3 ZEUS cardiovascular outcomes trial for ziltivekimab — an IL-6 pathway inhibitor — failed to demonstrate a statistically meaningful reduction in major adverse cardiovascular events versus placebo in patients with atherosclerotic cardiovascular disease, chronic...

Warmuth Markus (President & CEO) sold 9,500 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $23.18 ($0.22M total) on 2026-07-16.

Monte Rosa Therapeutics (Nasdaq: GLUE) said it granted inducement equity awards to three newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4). Awards include non-qualified stock options for 18,025 shares (exercise price $24.02) and restricted stock units for 3,900 shares, both subject to service-based vesting.

Manning Anthony M. sold 10,000 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $23.11 ($0.23M total) on 2026-06-29.

Janku Filip (Chief Medical Officer) sold 41,845 shares of Monte Rosa Therapeutics, Inc. (GLUE) at an average of $21.08 ($20.22–$21.42, $0.88M total) across 2 trades over 2026-06-23 to 2026-06-24 under a Rule 10b5-1 trading plan.

Monte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001826457 false 0001826457 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,

Monte Rosa Therapeutics (GLUE) reported May 7 progress in its clinical pipeline, with three programs moving toward Phase 2. MRT-8102 (NEK7) showed CRP reductions in early trials and plans multiple Phase 2 starts in H2 2026. MRT-6160 (VAV1) with Novartis and MRT-2359 (GSPT1) in mCRPC also advance, with a Phase 2 combo with apalutamide planned for Q3 2026. The company reported $671M cash, expected to fund operations into 2029.